Bradley Harrison
Family Medicine · Manhattan, KSNPI 1063553188
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $294,373 of the $313,588 with a category attached, or 93.9%. Novo Nordisk accounts for 95.1% of it on its own, with 42 other manufacturers making up the rest. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $470.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$298K
- Johnson & Johnson$11K
- Lilly USA, LLC$511
- AbbVie$473
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$381
- Amgen$378
- plus $3K from 37 others
What the payments were for
- Consulting fees$3750%
- Speaking & faculty fees$294,37394%
- Travel & lodging$10,3353%
- Food & beverage$8,4673%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$113,935
- Ozempic$108,106
- Tresiba$21,423
- INVOKANA$10,517
- Saxenda$3,740
- Xultophy 100/3.6$2,905
- ARES HOME SLEEP TESTING DEVICE$106
How this compares
$313,588 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 18 | $11,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,915 |
| Novolog FlexpenInsulin Aspart | 11 | $2,661 |
| Aripiprazole | 24 | $1,161 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $587 |
| Pregabalin | 16 | $459 |
| Montelukast Sodium | 18 | $281 |
| Losartan Potassium | 27 | $252 |
| Atorvastatin Calcium | 47 | $207 |
| Omeprazole | 23 | $201 |
| Levothyroxine Sodium | 28 | $189 |
| Carvedilol | 17 | $159 |
| Alendronate Sodium | 44 | $158 |
| Pioglitazone Hcl | 15 | $147 |
| Lisinopril | 34 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $331 | $8,91511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Manhattan
- Kent KiracofeManhattan$189K
- Kyle PlatzManhattan$51K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Eric AspinwallKansas City$28K
- Hai TruongWichita$25K
- Deborah OutwaterWichita$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.